{
    "name": "sofosbuvir",
    "comment": "Rx",
    "other_names": [
        "Sovaldi"
    ],
    "classes": [
        "Hepatitis B/Hepatitis C Agents",
        "HCV Polymerase Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/sovaldi-sofosbuvir-999890",
    "pregnancy": {
        "common": [
            "If therapy administered with ribavirin or peginterferon alfa and ribavirin, the combination regimen is contraindicated in pregnant women and in men whose female partners are pregnant; refer to ribavirin and/or peginterferon alfa prescribing information for more information on ribavirin-and peginterferon alfa-associated risks of use during pregnancy",
            "No adequate human data available to establish whether or not drug poses a risk to pregnancy outcomes"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In animal reproduction studies, no evidence of adverse developmental outcomes observed with sofosbuvir at exposures greater than those in humans at recommended human dose (RHD); during organogenesis in the rat and rabbit, systemic exposures (AUC) to predominant circulating metabolite of sofosbuvir (GS-331007) were ≥5 (rats) and 12 (rabbits) times the exposure in humans at the RHD; in the rat pre/postnatal development study, maternal systemic exposure (AUC) to GS-331007 was ≥6 times exposure in humans at RHD"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Not known whether sofosbuvir or metabolites are present in human breast milk, affect human milk production or have effects on breastfed infant; the predominant circulating metabolite of sofosbuvir (GS-331007) was the primary component observed in the milk of lactating rats, without effect on nursing pups",
            "The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for therapy and any potential adverse effects on breastfed child from drug or from underlying maternal condition",
            "If drug is administered with ribavirin, the nursing mother’s information for ribavirin also applies to this combination regimen; refer to ribavirin prescribing information for more information on use during lactation"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with HCV direct acting antivirals (DDAs)",
                "HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with DDAs and were not receiving HBV antiviral therapy",
                "Some cases have resulted in fulminant hepatitis, hepatic failure, and death",
                "Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up",
                "Initiate appropriate patient management for HBV infection as clinically indicated"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Contraindications applicable to combination therapy"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Hepatitis B virus (HBV) reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV DDAs, and who were not receiving HBV antiviral therapy; HBV reactivation is characterized as an abrupt increase in HBV replication manifesting as a rapid increase in serum HBV DNA level (see Black Box Warnings and Dosing Considerations)",
                "Drugs that are potent P-gp inducers in the intestine (eg, rifampin, St. John’s wort) may significantly decrease sofosbuvir plasma concentrations",
                "Serious symptomatic bradycardia may occur in coadministration with amiodarone in combination with another direct acting antiviral (DAA), particularly in patients also receiving beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease; coadministration is not recommended, if no alternative exists, inpatient cardiac monitoring is recommended for the first 48 hr and then daily home monitoring for at least the first 2 weeks",
                "Must NOT be used as monotherapy",
                "Use with other drugs containing sofosbuvir not recommended"
            ],
            "specific": [
                {
                    "type": "Combination with ribavirin",
                    "description": [
                        "Ribavirin may cause birth defects and fetal death; avoid pregnancy in female patients and female partners of male patients; patients must have a negative pregnancy test prior to therapy; use 2 or more forms of contraception, 1 of these forms of contraception can be a combined oral contraceptive product containing at least 1 mg of norethindrone (lower doses of norethindrone and other forms of hormonal contraception have not been studied or are contraindicated)",
                        "Risk of hemolytic anemia",
                        "Anemia associated with treatment may result in worsening of cardiac disease",
                        "Potential carcinogen effects",
                        "Ocular disorders reported when ribavirin is used in combination therapy with alpha interferons (eg, decrease or loss of vision, retinopathy including macular edema, retinal artery or vein, thrombosis, retinal hemorrhages; cotton wool spots, optic neuritis, papilledema, serous retinal detachment) ",
                        "Study in boys showed growth rate inhibited (ie, height percentile decreases) with peginterferon alfa-2b plus ribavirin ",
                        "Pancytopenia and bone marrow suppression reported when coadministered with pegylated interferon and azathioprine"
                    ]
                },
                {
                    "type": "Combination with peg-interferon alfa",
                    "description": [
                        "Discontinue STAT if progressive ALT increases despite dose reduction or accompanied with increased bilirubin or signs of hepatic decompensation",
                        "Caution in renal impairment",
                        "Risk of suicidal ideation and psychoses; discontinued if severe depression occurs",
                        "Safety and efficacy not been established in patients with liver and other transplantations; as with other alpha interferons, liver and renal graft rejections have been reported",
                        "May cause myelosuppression; discontinue therapy (at least temporarily) if platelet count <25,000/mm³ or ANC <500/mm³",
                        "Will likely experience flu-like symptoms in early part of treatment",
                        "May cause development of exacerbation of several pathologic conditions",
                        "Reduce/discontinue if moderate/severe depression, see Manufacturer's package insert",
                        "In hepatic impairment, reduce/discontinue as suggested by Manufacturer's package insert"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Frequent monitoring of relevant laboratory parameters (eg, International Normalized Ratio [INR] in patients taking warfarin, blood glucose levels in diabetic patients) or drug concentrations of concomitant medications such as cytochrome P450 substrates with a narrow therapeutic index (eg, certain immunosuppressants) is recommended to ensure safe and effective use; dose adjustments of concomitant medications may be necessary"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "amiodarone",
            "description": {
                "common": "sofosbuvir increases toxicity of amiodarone by unknown mechanism. Avoid or Use Alternate Drug. Postmarketing reports describe bradycardia resulting in death or pacemaker insertion when amiodarone was coadministered with sofosbuvir in combination with another direct acting antiviral. Patients also taking beta blockers (7 of 9 of the postmarketing reports), or those with underlying cardiac comorbidities and/or advanced liver disease may be at increased risk for symptomatic bradycardia with coadministration of amiodarone. If coadministration is required, cardiac monitoring in an inpatient setting for the first 48 hr of coadministration is recommended, after which outpatient or self-monitoring of the heart rate should occur on a daily basis through at least the first 2 weeks of treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine will decrease the level or effect of sofosbuvir by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. P-gp inducers decrease sofosbuvir levels, and therefore decrease conversion to sofosbuvir's active metabolite (GS-331007) responsible for 90% of pharmacologic effect"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "eliglustat",
            "description": {
                "common": "eliglustat increases levels of sofosbuvir by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the P-gp substrate and titrate to clinical effect."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "erdafitinib",
            "description": {
                "common": "erdafitinib will increase the level or effect of sofosbuvir by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. If coadministration unavoidable, separate administration by at least 6 hr before or after administration of P-gp substrates with narrow therapeutic index."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "fosphenytoin will decrease the level or effect of sofosbuvir by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. P-gp inducers decrease sofosbuvir levels, and therefore decrease conversion to sofosbuvir's active metabolite (GS-331007) responsible for 90% of pharmacologic effect"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lasmiditan",
            "description": {
                "common": "lasmiditan increases levels of sofosbuvir by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "leniolisib",
            "description": {
                "common": "leniolisib will increase the level or effect of sofosbuvir by  Other (see comment). Avoid or Use Alternate Drug. Leniolisib, a BCRP inhibitor, may increase systemic exposure of BCRP substrates"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oxcarbazepine",
            "description": {
                "common": "oxcarbazepine will decrease the level or effect of sofosbuvir by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. P-gp inducers decrease sofosbuvir levels, and therefore decrease conversion to sofosbuvir's active metabolite (GS-331007) responsible for 90% of pharmacologic effect"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital will decrease the level or effect of sofosbuvir by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. P-gp inducers decrease sofosbuvir levels, and therefore decrease conversion to sofosbuvir's active metabolite (GS-331007) responsible for 90% of pharmacologic effect"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phenytoin",
            "description": {
                "common": "phenytoin will decrease the level or effect of sofosbuvir by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. P-gp inducers decrease sofosbuvir levels, and therefore decrease conversion to sofosbuvir's active metabolite (GS-331007) responsible for 90% of pharmacologic effect"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rifabutin",
            "description": {
                "common": "rifabutin will decrease the level or effect of sofosbuvir by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. P-gp inducers decrease sofosbuvir levels, and therefore decrease conversion to sofosbuvir's active metabolite (GS-331007) responsible for 90% of pharmacologic effect"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rifampin",
            "description": {
                "common": "rifampin will decrease the level or effect of sofosbuvir by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. P-gp inducers decrease sofosbuvir levels, and therefore decrease conversion to sofosbuvir's active metabolite (GS-331007) responsible for 90% of pharmacologic effect"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rifapentine",
            "description": {
                "common": "rifapentine will decrease the level or effect of sofosbuvir by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. P-gp inducers decrease sofosbuvir levels, and therefore decrease conversion to sofosbuvir's active metabolite (GS-331007) responsible for 90% of pharmacologic effect"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sotorasib",
            "description": {
                "common": "sotorasib will decrease the level or effect of sofosbuvir by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. If use is unavoidable, refer to the prescribing information of the P-gp substrate for dosage modifications."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "St John's Wort",
            "description": {
                "common": "St John's Wort will decrease the level or effect of sofosbuvir by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. P-gp inducers decrease sofosbuvir levels, and therefore decrease conversion to sofosbuvir's active metabolite (GS-331007) responsible for 90% of pharmacologic effect"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tepotinib",
            "description": {
                "common": "tepotinib will increase the level or effect of sofosbuvir by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. If concomitant use unavoidable, reduce the P-gp substrate dosage if recommended in its approved product labeling."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tipranavir",
            "description": {
                "common": "tipranavir will decrease the level or effect of sofosbuvir by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. P-gp inducers decrease sofosbuvir levels, and therefore decrease conversion to sofosbuvir's active metabolite (GS-331007) responsible for 90% of pharmacologic effect"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acalabrutinib",
            "description": {
                "common": "acalabrutinib increases levels of sofosbuvir by Other (see comment). Use Caution/Monitor. \nComment: Acalabrutinib may increase exposure to coadministered BCRP substrates by inhibition of intestinal BCRP."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "apalutamide",
            "description": {
                "common": "apalutamide will decrease the level or effect of sofosbuvir by  increasing elimination. Use Caution/Monitor. Apalutamide weakly induces BCRP and may decrease systemic exposure of drugs that are BCRP substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "berotralstat",
            "description": {
                "common": "berotralstat will increase the level or effect of sofosbuvir by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Monitor or titrate P-gp substrate dose if coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "darolutamide",
            "description": {
                "common": "darolutamide will increase the level or effect of sofosbuvir by  Other (see comment). Modify Therapy/Monitor Closely. Darolutamide is a BCRP inhibitor. Avoid coadministration with BCRP inhibitors. If use is unavoidable, closely monitor for adverse reactions and consider dose reduction of BCRP substrate drug (refer BCRP substrate prescribing information)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elagolix",
            "description": {
                "common": "elagolix will increase the level or effect of sofosbuvir by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elvitegravir/cobicistat/emtricitabine/tenofovir DF",
            "description": {
                "common": "sofosbuvir will increase the level or effect of elvitegravir/cobicistat/emtricitabine/tenofovir DF by  unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "encorafenib",
            "description": {
                "common": "encorafenib will increase the level or effect of sofosbuvir by  Other (see comment). Modify Therapy/Monitor Closely. Encorafenib (a BCRP inhibitor) may increase the concentration and toxicities of BCRP substrates. Closely monitor for signs and symptoms of increased exposure and consider adjusting the dose of these substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fostemsavir",
            "description": {
                "common": "fostemsavir will increase the level or effect of sofosbuvir by  Other (see comment). Modify Therapy/Monitor Closely. Fostemsavir inhibits BCRP transporters. If possible, avoid coadministration or modify dose of BCRP substrate coadministered with fostemsavir. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "istradefylline",
            "description": {
                "common": "istradefylline will increase the level or effect of sofosbuvir by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of P-gp substrates in clinical trials. Consider dose reduction of sensitive P-gp substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lonafarnib",
            "description": {
                "common": "lonafarnib will increase the level or effect of sofosbuvir by  P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Lonafarnib is a weak P-gp inhibitor. Monitor for adverse reactions if coadministered with P-gp substrates where minimal concentration changes may lead to serious or life-threatening toxicities. Reduce P-gp substrate dose if needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oteseconazole",
            "description": {
                "common": "oteseconazole will increase the level or effect of sofosbuvir by  Other (see comment). Modify Therapy/Monitor Closely. Otesezonale, a BCRP inhibitor, may increase the effects and risk of toxicities of BCRP substrates. Use lowest starting dose of BCRP substrate, or consider reducing BCRP substrate dose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "regorafenib",
            "description": {
                "common": "regorafenib will increase the level or effect of sofosbuvir by  Other (see comment). Modify Therapy/Monitor Closely. Regorafenib likely inhibits BCRP (ABCG2) transport. Coadministration with a BCRP substrate may increase systemic exposure to the substrate and related toxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "safinamide",
            "description": {
                "common": "safinamide will increase the level or effect of sofosbuvir by  Other (see comment). Use Caution/Monitor. Safinamide and its major metabolite may inhibit intestinal BCRP. Monitor BCRP substrates for increased pharmacologic or adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sarecycline",
            "description": {
                "common": "sarecycline will increase the level or effect of sofosbuvir by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Monitor for toxicities of P-gp substrates that may require dosage reduction when coadministered with P-gp inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "stiripentol",
            "description": {
                "common": "stiripentol will increase the level or effect of sofosbuvir by  Other (see comment). Modify Therapy/Monitor Closely. Stiripentol is a BCRP transport inhibitor. Consider dosage reduction for BCRP substrates if adverse effects are experienced when coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tafamidis",
            "description": {
                "common": "tafamidis will increase the level or effect of sofosbuvir by  Other (see comment). Use Caution/Monitor. Tafamidis inhibits breast cancer resistant protein (BCRP) in vitro and may increase exposure of BCRP substrates following tafamidis or tafamidis meglumine administration. Dosage adjustment of these BCRP substrates may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tafamidis meglumine",
            "description": {
                "common": "tafamidis meglumine will increase the level or effect of sofosbuvir by  Other (see comment). Use Caution/Monitor. Tafamidis inhibits breast cancer resistant protein (BCRP) in vitro and may increase exposure of BCRP substrates following tafamidis or tafamidis meglumine administration. Dosage adjustment of these BCRP substrates may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tenofovir DF",
            "description": {
                "common": "sofosbuvir will increase the level or effect of tenofovir DF by  unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tucatinib",
            "description": {
                "common": "tucatinib will increase the level or effect of sofosbuvir by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Consider reducing the dosage of P-gp substrates, where minimal concentration changes may lead to serious or life-threatening toxicities."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Fatigue",
            "percent": "38"
        },
        {
            "name": "Headache",
            "percent": "24"
        },
        {
            "name": "Nausea",
            "percent": "22"
        },
        {
            "name": "Insomnia",
            "percent": "15"
        },
        {
            "name": "Pruritus",
            "percent": "11"
        },
        {
            "name": "Fatigue",
            "percent": "30"
        },
        {
            "name": "Headache",
            "percent": "30"
        },
        {
            "name": "Nausea",
            "percent": "13"
        },
        {
            "name": "Insomnia",
            "percent": "16"
        },
        {
            "name": "Pruritus",
            "percent": "27"
        },
        {
            "name": "Asthenia",
            "percent": "21"
        },
        {
            "name": "Diarrhea",
            "percent": "12"
        },
        {
            "name": "Fatigue",
            "percent": "59"
        },
        {
            "name": "Headache",
            "percent": "36"
        },
        {
            "name": "Nausea",
            "percent": "34"
        },
        {
            "name": "Insomnia",
            "percent": "25"
        },
        {
            "name": "Pruritus",
            "percent": "17"
        },
        {
            "name": "Anemia",
            "percent": "21"
        },
        {
            "name": "Rash",
            "percent": "18"
        },
        {
            "name": "Decreased appetite",
            "percent": "18"
        },
        {
            "name": "Chills",
            "percent": "17"
        },
        {
            "name": "Influenza",
            "percent": "16"
        },
        {
            "name": "like illness",
            "percent": "18"
        },
        {
            "name": "Pyrexia",
            "percent": "12"
        },
        {
            "name": "Diarrhea",
            "percent": "17"
        },
        {
            "name": "Neutropenia",
            "percent": "14"
        },
        {
            "name": "Myalgia",
            "percent": "13"
        },
        {
            "name": "Irritability",
            "percent": "55"
        },
        {
            "name": "Fatigue",
            "percent": "44"
        },
        {
            "name": "Headache",
            "percent": "29"
        },
        {
            "name": "Nausea",
            "percent": "29"
        },
        {
            "name": "Insomnia",
            "percent": "17"
        },
        {
            "name": "Pruritus",
            "percent": "12"
        },
        {
            "name": "Anemia",
            "percent": "18"
        },
        {
            "name": "Rash",
            "percent": "18"
        },
        {
            "name": "Decreased appetite",
            "percent": "18"
        },
        {
            "name": "Chills",
            "percent": "18"
        },
        {
            "name": "Influenza",
            "percent": "14"
        },
        {
            "name": "like illness",
            "percent": "17"
        },
        {
            "name": "Pyrexia",
            "percent": "12"
        },
        {
            "name": "Diarrhea",
            "percent": "16"
        },
        {
            "name": "Neutropenia",
            "percent": "16"
        },
        {
            "name": "Myalgia",
            "percent": "10"
        },
        {
            "name": "Irritability",
            "percent": "6"
        },
        {
            "name": "Anemia",
            "percent": "8"
        },
        {
            "name": "Asthenia",
            "percent": "6"
        },
        {
            "name": "Rash",
            "percent": "2"
        },
        {
            "name": "Decreased appetite",
            "percent": "3"
        },
        {
            "name": "Chills",
            "percent": "4"
        },
        {
            "name": "Influenza",
            "percent": "9"
        },
        {
            "name": "like sickness",
            "percent": "6"
        },
        {
            "name": "Pyrexia",
            "percent": "10"
        },
        {
            "name": "Diarrhea",
            "percent": "6"
        },
        {
            "name": "Myalgia",
            "percent": "9"
        },
        {
            "name": "Irritability",
            "percent": "6"
        },
        {
            "name": "Anemia",
            "percent": "2"
        },
        {
            "name": "Rash",
            "percent": "6"
        },
        {
            "name": "Decreased appetite",
            "percent": "4"
        },
        {
            "name": "Chills",
            "percent": "9"
        },
        {
            "name": "Influenza",
            "percent": "10"
        },
        {
            "name": "like sickness",
            "percent": null
        },
        {
            "name": "Pyrexia",
            "percent": null
        },
        {
            "name": "Myalgia",
            "percent": null
        },
        {
            "name": "Irritability",
            "percent": null
        }
    ]
}